Penetration of aztreonam into human cerebrospinal fluid in the presence of meningeal inflammation.
Cerebrospinal fluid of aztreonam were measured in 11 patients with meningeal inflammation. Two to eight hours after a single 2 gm intravenous dose, CSF aztreonam levels ranged from 0.76 to 16.6 mg/l. The mean CSF concentration in four patients with viral meningitis was 1.28 mg/l, which was lower than the mean concentration of 7.2 mg/l in the five with bacterial, cryptococcal or carcinomatous meningitis. Two patients with infected subdural drains were also sampled serially and had CSF levels greater than 1 mg/l between 1 and 8 h post dose. Penetration of aztreonam into the CSF in the presence of meningeal inflammation appears adequate to warrant therapeutic trials in patients infected with susceptible organisms.
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000134:cerebrospinal fluid*; D001398:Aztreonam; D005260:Female; D006801:Humans; D008297:Male; D008581:Meningitis / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D008585:Meningitis, Meningococcal / Q000134:cerebrospinal fluid; D008587:Meningitis, Viral / Q000134:cerebrospinal fluid; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D001398:Aztreonam